Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, generalized HSDD—not men, performance enhancement or a generic PT-141 research material.
Evidence at a glance
- The two phase 3 trials randomized 1,267 women; 1,202 were in the efficacy population.
- Between-group changes favored bremelanotide for desire and distress endpoints, but a post-hoc satisfying-event measure did not differ significantly.
- Nausea, flushing and headache occurred in at least 10% and were more common than with placebo.
Study record
The co-primary endpoints were change in the FSFI desire-domain score and a distress item from the FSDS-DAO. Study-specific desire differences were 0.30 and 0.42; distress differences were −0.37 and −0.29. Statistical significance does not by itself describe the size or relevance of benefit for every individual.
Results in context
The paper reports no significant group difference in the percentage of satisfying sexual events in a post-hoc analysis. Preserving that null finding keeps the record more informative than a benefits-only summary.
Current DailyMed labeling identifies Vyleesi as bremelanotide injection under NDA 210557 and lists transient blood-pressure increase, heart-rate decrease, nausea and focal hyperpigmentation among important safety information. This label belongs to the approved formulation, not to a research catalog item.
What the evidence cannot establish
The evidence population and indication are specific; broader sexual-performance claims are unsupported.
The pivotal trials were industry funded.
An approved active moiety does not make an independently sourced material an approved drug.
Sources & editorial method
The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, study size, model/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- RECONNECT bremelanotide phase 3 trialsPrimary phase 3 publication; PMID 31599840.
- DailyMed Vyleesi prescribing informationCurrent FDA-approved finished-drug label.
- PubChem Bremelanotide recordFree-base peptide identity; CID 9941379.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
